{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:33:45Z","timestamp":1786739625927,"version":"build-2736575974"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:p>The Michael J. Fox Foundation has been funding research on Parkinson\u2019s disease for 35 years, but has yet to find a cure. This is due to a problem with the philosophy behind the development of modern medical treatments. In this paper, we will introduce \u201csmart medicine\u201d with a substance that can solve all the problems of central nervous system drugs. The substance is the smallest diatomic molecule, the hydrogen molecule. Due to their size, hydrogen molecules can easily penetrate the cell membrane and enter the brain. In the midbrain of Parkinson\u2019s disease patients, hydroxyl radicals generated by the Fenton reaction cause a chain reaction of oxidation of dopamine, but hydrogen entering the midbrain can convert the hydroxyl radicals into water molecules and inhibit the oxidation of dopamine. In this paper, we focus on the etiology of neurological diseases, especially Parkinson\u2019s disease, and present a case in which hydrogen inhalation improves the symptoms of Parkinson\u2019s disease, such as body bending and hand tremor. And we confidently state that if Michael J. Fox encountered \u201csmart medicine\u201d that could be realized with molecular hydrogen, he would not be a \u201clucky man\u201d but a \u201csuper-lucky man.\u201d<\/jats:p>","DOI":"10.4103\/2045-9912.385949","type":"journal-article","created":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T06:10:16Z","timestamp":1694844616000},"page":"89-95","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Realizing brain therapy with \u201csmart medicine\u201d: mechanism and case report of molecular hydrogen inhalation for Parkinson\u2019s disease"],"prefix":"10.4103","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2526-4681","authenticated-orcid":false,"given":"Yusuke","family":"Ichikawa","sequence":"first","affiliation":[{"name":"Research and Development Department, MiZ Company Limited, Kanagawa, Japan"},{"name":"MiZ Inc., Newark, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bunpei","family":"Sato","sequence":"additional","affiliation":[{"name":"Research and Development Department, MiZ Company Limited, Kanagawa, Japan"},{"name":"MiZ Inc., Newark, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8610-8922","authenticated-orcid":false,"given":"Shin-ichi","family":"Hirano","sequence":"additional","affiliation":[{"name":"Research and Development Department, MiZ Company Limited, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1826-742X","authenticated-orcid":false,"given":"Yoshiyasu","family":"Takefuji","sequence":"additional","affiliation":[{"name":"Faculty of Data Science, Musashino University, Tokyo, Japan"},{"name":"Keio University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitake","family":"Satoh","sequence":"additional","affiliation":[{"name":"Research and Development Department, MiZ Company Limited, Kanagawa, Japan"},{"name":"MiZ Inc., Newark, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,9,17]]},"reference":[{"key":"R1-20250415","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1038\/d41586-019-02214-2","article-title":"The ethics of brain-computer interfaces","volume":"571","author":"Drew","year":"2019","journal-title":"Nature"},{"key":"R2-20250415","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/551159a","article-title":"Four ethical priorities for neurotechnologies and AI","volume":"551","author":"Yuste","year":"2017","journal-title":"Nature"},{"key":"R3-20250415","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3389\/fnins.2014.00404","article-title":"The rights and wrongs of blood-brain barrier permeability studies: a walk through 100 years of history","volume":"8","author":"Saunders","year":"2014","journal-title":"Front Neurosci"},{"key":"R4-20250415","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"R5-20250415","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3233\/JPD-202004","article-title":"GDNF and Parkinson\u2019s disease: where next? a summary from a recent workshop","volume":"10","author":"Barker","year":"2020","journal-title":"J Parkinsons Dis"},{"key":"R6-20250415","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/j.1471-4159.1989.tb07264.x","article-title":"Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease","volume":"52","author":"Dexter","year":"1989","journal-title":"J Neurochem"},{"key":"R7-20250415","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1471-4159.1989.tb09150.x","article-title":"Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains","volume":"52","author":"Riederer","year":"1989","journal-title":"J Neurochem"},{"key":"R8-20250415","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0034-5687(01)00306-1","article-title":"Tissue oxygen tension and brain sensitivity to hypoxia","volume":"128","author":"Erecmska","year":"2001","journal-title":"Respir Physiol"},{"key":"R9-20250415","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1212\/WNL.0b013e3181a26b30","article-title":"Brain iron homeostasis and neurodegenerative disease","volume":"72","author":"Benarroch","year":"2009","journal-title":"Neurology"},{"key":"R10-20250415","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00415-002-0704-6","article-title":"Association study between iron-related genes polymorphisms and Parkinson\u2019s disease","volume":"249","author":"Borie","year":"2002","journal-title":"J Neurol"},{"key":"R11-20250415","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.spen.2006.08.008","article-title":"Iron: a new target for pharmacological intervention in neurodegenerative diseases","volume":"13","author":"Whitnall","year":"2006","journal-title":"Semin Pediatr Neurol"},{"key":"R12-20250415","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1179\/1351000213Y.0000000065","article-title":"Tocot-rienol prevents AAPH-induced neurite degeneration in neuro2a cells","volume":"18","author":"Fukui","year":"2013","journal-title":"Redox Rep"},{"key":"R13-20250415","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3109\/10715762.2011.647689","article-title":"Tocotrienols prevent hydrogen peroxide-induced axon and dendrite degeneration in cerebellar granule cells","volume":"46","author":"Fukui","year":"2012","journal-title":"Free Radic Res"},{"key":"R14-20250415","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4103\/2045-9912.296045","article-title":"Proposal of next-generation medical care \u201cMega-hydrogen Therapy\u201d","volume":"10","author":"Ichikawa","year":"2020","journal-title":"Med Gas Res"},{"key":"R15-20250415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02251241","article-title":"Neuromelanin synthesis in rat and human substantia nigra","volume":"2","author":"Rabey","year":"1990","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"R16-20250415","doi-asserted-by":"crossref","first-page":"41890","DOI":"10.1074\/jbc.M306017200","article-title":"Parkin cleaves intracellular alpha-synuclein inclusions via the activation of calpain","volume":"278","author":"Kim","year":"2003","journal-title":"J Biol Chem"},{"key":"R17-20250415","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nrn983","article-title":"Pathogenesis of Parkinson\u2019s disease: dopamine, vesicles and alpha-synuclein","volume":"3","author":"Lotharius","year":"2002","journal-title":"Nat Rev Neurosci"},{"key":"R18-20250415","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.freeradbiomed.2006.12.004","article-title":"Molecular mechanisms of 6-hy-droxydopamine-induced cytotoxicity in PC12 cells: involvement of hydrogen peroxide-dependent and -independent action","volume":"42","author":"Saito","year":"2007","journal-title":"Free Radic BiolMed"},{"key":"R19-20250415","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.neulet.2009.02.016","article-title":"Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson\u2019s disease","volume":"453","author":"Fu","year":"2009","journal-title":"Neurosci Lett"},{"key":"R20-20250415","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1471-4159.1990.tb08814.x","article-title":"Decreased ferritin levels in brain in Parkinson\u2019s disease","volume":"55","author":"Dexter","year":"1990","journal-title":"J Neurochem"},{"key":"R21-20250415","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1750-1326-6-8","article-title":"Glutathione peroxidase 4 is associated with neuromelanin in substantia nigra and dystrophic axons in putamen of Parkinson\u2019s brain","volume":"6","author":"Bellinger","year":"2011","journal-title":"Mol Neurodegener"},{"issue":"Suppl 1","key":"R22-20250415","first-page":"24","article-title":"Oxidative mechanisms in nigral cell death in Parkinson\u2019s disease","volume":"13","author":"Jenner","year":"1998","journal-title":"Mov Disord"},{"key":"R23-20250415","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0378-5173(02)00457-X","article-title":"Recent advances in the brain-to-blood efflux transport across the blood-brain barrier","volume":"248","author":"Hosoya","year":"2002","journal-title":"Int J Pharm"},{"key":"R24-20250415","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1002\/jps.21745","article-title":"In vivo, in vitro and in silico methods for small molecule transfer across the BBB","volume":"98","author":"Mensch","year":"2009","journal-title":"J Pharm Sci"},{"key":"R25-20250415","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","article-title":"Medicinal chemical properties of successful central nervous system drugs","volume":"2","author":"Pajouhesh","year":"2005","journal-title":"NeuroRx"},{"key":"R26-20250415","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.addr.2008.04.016","article-title":"Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases","volume":"60","author":"Yamada","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"R27-20250415","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3390\/biom10010083","article-title":"Therapeutic strategies for regulating mitochondrial oxidative stress","volume":"10","author":"Yamada","year":"2020","journal-title":"Biomolecules"},{"key":"R28-20250415","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/0024-3205(92)90537-Y","article-title":"P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells","volume":"51","author":"Tsuji","year":"1992","journal-title":"Life Sci"},{"key":"R29-20250415","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/mds.27360","article-title":"Disease modification in Parkinson\u2019s disease: current approaches, challenges, and future considerations","volume":"33","author":"Lang","year":"2018","journal-title":"Mov Disord"},{"key":"R30-20250415","article-title":"Awakenings","author":"Sacks","year":"1973","journal-title":"Vintage"},{"key":"R31-20250415","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/mds.25364","article-title":"Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease","volume":"28","author":"Warren","year":"2013","journal-title":"Mov Disord"},{"key":"R32-20250415","doi-asserted-by":"crossref","first-page":"7211","DOI":"10.3390\/ijms22137211","article-title":"Molecular hydrogen as a novel protective agent against pre-symptomatic diseases","volume":"22","author":"Yamamoto","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R33-20250415","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/2045-9912.248264","article-title":"Inhalation of hydrogen gas elevates urinary 8-hydroxy-2'-deoxyguanine in Parkinson\u2019s disease","volume":"8","author":"Hirayama","year":"2018","journal-title":"Med Gas Res"},{"key":"R34-20250415","article-title":"Lucky Man: A Memoir","author":"Fox","year":"2002","journal-title":"Hachette Books"},{"key":"R35-20250415","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/mds.10640","article-title":"Michael J. Fox and his Parkinson\u2019s disease","volume":"19","author":"Kempster","year":"2004","journal-title":"Mov Disord"},{"key":"R36-20250415","first-page":"1316","article-title":"A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson\u2019s Research","volume":"6","author":"Baptista","year":"2013","journal-title":"Dis Model Mech"},{"key":"R37-20250415","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4103\/2045-9912.266996","article-title":"Preventing explosions of hydrogen gas inhalers","volume":"9","author":"Kurokawa","year":"2019","journal-title":"Med Gas Res"},{"key":"R38-20250415","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2015.02.047","article-title":"Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis","volume":"161","author":"Yano","year":"2015","journal-title":"Cell"},{"key":"R39-20250415","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/mi.2010.29","article-title":"A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demy-elinating disease","volume":"3","author":"Ochoa-Rep\u00e1raz","year":"2010","journal-title":"Mucosal Immunol"},{"key":"R40-20250415","doi-asserted-by":"crossref","first-page":"19227","DOI":"10.1038\/s41598-019-55851-y","article-title":"The relationship between the gut microbiome and mild cognitive impairment in patients without dementia: a cross-sectional study conducted in Japan","volume":"9","author":"Saji","year":"2019","journal-title":"Sci Rep"},{"key":"R41-20250415","doi-asserted-by":"crossref","first-page":"e0142164","DOI":"10.1371\/journal.pone.0142164","article-title":"Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson\u2019s disease","volume":"10","author":"Hasegawa","year":"2015","journal-title":"PLoS One"}],"container-title":["Medical Gas Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/2045-9912.385949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:30:39Z","timestamp":1786735839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/2045-9912.385949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,17]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/2045-9912.385949","relation":{},"ISSN":["2045-9912"],"issn-type":[{"value":"2045-9912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,17]]},"assertion":[{"value":"2022-02-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}